Intravenous irinotecan plus oral ciclosporin

Clinical Oncology

Volumn 17, Issue 8, 2005, Pages 646-649

  Vasudev, N S ^a   Jagdev, S ^a   Anthoney, D A ^a   Seymour, Matt T ^a  

^a Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

Ciclosporin; Colorectal cancer; Irinotecan

Indexed keywords

CISPLATIN; CYCLOSPORIN A; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ABDOMINAL CRAMP; ADULT; AGED; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; ESOPHAGUS CANCER; FEMALE; HUMAN; LETHARGY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYCLOSPORINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 28244473065     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.06.009     Document Type: Article

References (13)

1. K. Goto I. Sekine Y. Nishiwaki R. Kakinuma et al Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer Br J Cancer 91 2004 659-665
2. C. Pozzo C. Barone J. Szanto et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study Ann Oncol 15 2004 1773-17781
3. M.L. Rothenberg N.J. Meropol E.A. Poplin E. Van Cutsem S. Wadler Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801-3807
4. D.F. Kehrer W. Yamamoto J. Verweij M.J. de Jonge P. de Bruijn A. Sparreboom Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies Clin Cancer Res 6 2000 3451-3458
5. E. Gupta T.M. Lestingi R. Mick J. Ramirez E.E. Vokes M.J. Ratain Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea Cancer Res 54 1994 3723-3725
6. L.E. Carlini N.J. Meropol J. Bever et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan Clin Cancer Res 11 2005 1226-1236
7. E. Gupta A.R. Safa X. Wang M.J. Ratain Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A Cancer Res 56 1996 1309-1314
8. J.D. Chester S.P. Joel S.L. Cheeseman et al. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer J Clin Oncol 21 2003 1125-1132
9. C. Köhne J. de Greve C. Bokemeyer et al Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015 [abstract 3525] Proc Am Soc Clin Oncol 2005 24
10. D. Cunningham S. Pyrhonen R.D. James et al Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413-1418
11. C.S. Fuchs M.R. Moore G. Harker L. Villa D. Rinaldi J.R. Hecht Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807-814
12. M.J. Ratain B.C. Goh L. Iyer et al. A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB) [abstract 777] Proc Am Soc Clin Oncol 18 1999 202a
13. M.L. Rothenberg J.G. Kuhn L.J. Schaaf et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks Ann Oncol 12 2001 1631-1641